{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-068002","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.351212+00:00","generated_at":"2026-06-04T18:47:23.916568+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Plus Therapeutics receives Nasdaq delisting notice for equity deficiency","bullets":["Stockholders' equity was ($1,348,000) as of Dec 31, 2023, below Nasdaq's $2.5M minimum.","Company has 45 days (until Apr 22, 2024) to submit a plan to regain compliance.","If accepted, Nasdaq may grant up to 180 days (until Sep 4, 2024) to cure the deficiency.","Company plans to pursue capital raising to satisfy the equity or alternative standards.","Failure to regain compliance could result in delisting of PSTV common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-068002","json":"https://secwatch.observer/filing/0001193125-24-068002.json","markdown":"https://secwatch.observer/filing/0001193125-24-068002.md","text":"https://secwatch.observer/filing/0001193125-24-068002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312524068002/0001193125-24-068002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312524068002/d794768d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T18:47:23.916568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"980858a7f1748f6facdb4d51d7e282d611ea3706","claim":"PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"March 8, 2024, Plus Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”) or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000119312524068002/0001193125-24-068002-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}